Last reviewed · How we verify
Fibrinolytic twice daily
Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi.
Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.
At a glance
| Generic name | Fibrinolytic twice daily |
|---|---|
| Also known as | lytics twice daily, tPA twice daily |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Fibrinolytic agent |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fibrinolytic drugs work by converting the inactive zymogen plasminogen into its active form, plasmin, a serine protease that degrades fibrin—the structural protein that stabilizes blood clots. This mechanism enables dissolution of existing thrombi in conditions such as acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. The twice-daily dosing regimen suggests a formulation designed for sustained or repeated fibrinolytic activity.
Approved indications
- Acute myocardial infarction
- Acute ischemic stroke
- Pulmonary embolism
- Deep vein thrombosis
Common side effects
- Bleeding (major and minor)
- Intracranial hemorrhage
- Allergic reactions
- Hypotension
Key clinical trials
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) (PHASE2)
- Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (PHASE4)
- Pleural Space Saline Irrigation in Addition to Standard Intrapleural Thrombolytic Therapy in Empyema/Complicated Parapneumonic Effusion (NA)
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care (PHASE3)
- Early Intrapleural TPA Instillation Versus Late (PHASE4)
- Fibrinolytic Therapy Versus Medical Thoracoscopy (PHASE4)
- Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities (PHASE3)
- Management of Pleural Space Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrinolytic twice daily CI brief — competitive landscape report
- Fibrinolytic twice daily updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI